Home > Insider Trading > Filing (0001209191-23-014280)

Filing Details

Accession Number:: 0001209191-23-014280
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-03-01 18:21:08
Reporting Period:: 2023-02-27

Accepted Time:: 2023-03-01 18:21:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1446847	Ironwood Pharmaceuticals Inc	IRWD	Pharmaceutical Preparations (2834)	043404176

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1808509	Michael Shetzline	C/O Ironwood Pharmaceuticals, Inc. 100 Summer Street, Suite 2300 Boston MA 02110	Cmo,Svp,Head-Res&Drug	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Disposition	2023-02-27	7,146	$11.41	273,762	No	4	S	Direct
Class A Common Stock	Disposition	2023-02-27	2,322	$11.41	271,440	No	4	S	Direct
Class A Common Stock	Disposition	2023-02-28	7,438	$11.31	264,002	No	4	S	Direct
Class A Common Stock	Disposition	2023-02-28	2,416	$11.31	261,586	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units granted on February 27, 2020 and April 24, 2020. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.